CD4 and graft versus host disease: Since experimental data have shown a clear benefit of the transfer of CD4+CD25+ Tregs in the prevention and treatment of GVHD in mouse models (26, 27) and in human allograft recipients (28), we analyzed the impact of Treg suppression of GVHD on MCMV reactivation.